US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Decoy Therapeutics Inc

0.7080

+0.00680.97%

Post-market: 0.70800.00000.00%17:48 EST

Volume:53.61K

Turnover:37.43K

Market Cap:4.52M

PE:-0.02

High:0.7299

Open:0.7000

Low:0.6800

Close:0.7012

52wk High:34.65

52wk Low:0.5148

Shares:6.38M

Float Shares:6.34M

Volume Ratio:0.52

T/O Rate:0.85%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-39.1909

EPS(LYR):-86.9214

ROE:-139.55%

ROA:-69.91%

PB:1.06

PE(LYR):-0.01

Loading ...

Overview Company News Filings

Decoy Therapeutics Showcases Antiviral Platform at Webull Financial Corporate Connect Webinar

Decoy Therapeutics gibt Global Access Commitment Agreement mit Gates Foundation bekannt

Decoy Therapeutics Participates in Virtual Investor "What This Means" Segment Highlighting Recently Announced Global Access Commitment Agreement

THOMSON REUTERS

Decoy Therapeutics initiated with a Buy at Ladenburg

BUZZ-U.S. STOCKS ON THE MOVE-Cardinal Health, Decoy Therapeutic

BUZZ-Decoy Therapeutics rises as Gates Foundation backs antiviral drug access

Decoy Therapeutics Advances Pan-Coronavirus Antiviral Toward FDA IND Filing

Decoy Therapeutics Reaches Global Access Commitment Agreement to Focus on Development of a Globally Accessible, Scalable Peptide-Conjugate Manufacturing Platform

THOMSON REUTERS

Decoy Therapeutics Inc - Expects to File Ind Application for Pan-Coronavirus Antiviral

THOMSON REUTERS

BRIEF-Salarius Pharmaceuticals Changes Name To Decoy Therapeutics

Salarius Pharmaceuticals Inc - Changes Name to Decoy Therapeutics

THOMSON REUTERS

Salarius Pharmaceuticals Inc - Trading Under Dcoy to Commence on January 8, 2026

THOMSON REUTERS

Salarius Pharmaceuticals Rebrands as Decoy Therapeutics

Top Midday Decliners

MT Newswires Live

Nasdaq Moves to Delist Salarius Pharmaceuticals Over Minimum Bid Price Violation

Director Arnold C. Hanish Reports Disposal of Salarius Pharmaceuticals Inc. Common Shares

Salarius Pharmaceuticals Inc. held annual shareholder meeting

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/DCOY/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"DCOY","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DCOY\",,,,,undefined,":{"symbol":"DCOY","market":"US","secType":"STK","nameCN":"Decoy Therapeutics Inc","latestPrice":0.708,"timestamp":1771966800000,"preClose":0.7012,"halted":0,"volume":53605,"hourTrading":{"tag":"盘后","latestPrice":0.708,"preClose":0.708,"latestTime":"17:48 EST","volume":6,"amount":4.233,"timestamp":1771973318119,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.009697661152310206,"floatShares":6341106,"shares":6384200,"eps":-39.1909,"marketStatus":"Not Yet Opened","change":0.0068,"latestTime":"02-24 16:00:00 EST","open":0.7,"high":0.7299,"low":0.68,"amount":37430.991171249996,"amplitude":0.071164,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-39.1909,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1772010000000},"marketStatusCode":0,"adr":0,"listingDate":1422507600000,"exchange":"NASDAQ","adjPreClose":0.7012,"preHourTrading":{"tag":"盘前","latestPrice":0.7012,"preClose":0.7012,"latestTime":"08:22 EST","volume":27,"amount":18.9324,"timestamp":1771939346234,"change":0,"changeRate":0,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":0.708,"preClose":0.708,"latestTime":"17:48 EST","volume":6,"amount":4.233,"timestamp":1771973318119,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.521742},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DCOY\",,,,,undefined,":{"symbol":"DCOY","floatShares":6341106,"roa":"-69.91%","roe":"-139.55%","lyrEps":-86.921415,"volumeRatio":0.521742,"shares":6384200,"dividePrice":0,"high":0.7299,"amplitude":0.071164,"preClose":0.7012,"low":0.68,"week52Low":0.5148,"pbRate":"1.06","week52High":34.65,"institutionHeld":0,"latestPrice":0.708,"eps":-39.1909,"divideRate":0,"volume":53605,"delay":0,"ttmEps":-39.1909,"open":0.7,"prevYearClose":0.6488,"prevWeekClose":0.7422,"prevMonthClose":0.7709,"prevQuarterClose":0.6488,"fiveDayClose":0.7499,"twentyDayClose":0.803,"sixtyDayClose":0.8827},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/DCOY\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"DCOY\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"DCOY\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/DCOY\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"DCOY","date":"2026-02-23","current":-0.018065,"percent":0.766667,"low":-1.594527,"twenty":-1.05749,"median":-0.983377,"eighty":-0.942429,"high":-0.790885,"avg":-1.012473,"sd":0.1393,"marketCap":4738336},"quantilePoints":[{"date":"2026-01-09","current":-0.982229,"twenty":-1.053663,"median":-1.026876,"eighty":-1.000088,"marketCap":4915816},{"date":"2026-01-16","current":-1.227403,"twenty":-1.203881,"median":-1.071522,"eighty":-1.040856,"marketCap":6142855},{"date":"2026-01-23","current":-0.957354,"twenty":-1.160688,"median":-1.045754,"eighty":-0.982229,"marketCap":4791324},{"date":"2026-01-30","current":-1.05749,"twenty":-1.109791,"median":-1.050666,"eighty":-0.994985,"marketCap":5292482},{"date":"2026-02-06","current":-0.790885,"twenty":-1.101882,"median":-1.039631,"eighty":-0.91832,"marketCap":3958189},{"date":"2026-02-13","current":-0.956844,"twenty":-1.071522,"median":-0.994921,"eighty":-0.926101,"marketCap":4788771},{"date":"2026-02-20","current":-1.018456,"twenty":-1.060296,"median":-0.989117,"eighty":-0.939163,"marketCap":5097126},{"date":"2026-02-23","current":-0.946766,"twenty":-1.05749,"median":-0.983377,"eighty":-0.942429,"marketCap":4738336}],"updateTime":1772003894940},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"DCOY\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2609306791","title":"Decoy Therapeutics Showcases Antiviral Platform at Webull Financial Corporate Connect Webinar","url":"https://stock-news.laohu8.com/highlight/detail?id=2609306791","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609306791?lang=en_us&edition=fundamental","pubTime":"2026-02-05 22:15","pubTimestamp":1770300929,"startTime":"0","endTime":"0","summary":"Decoy Therapeutics Inc. will participate in the Corporate Connect Webinar Series hosted by Webull Financial, taking place virtually on February 10-11, 2026. The company's Chief Executive Officer, Rick Pierce, is scheduled to give a corporate overview and discuss their new class of antiviral therapeutics on Tuesday, February 10, 2026, at 1:20 PM EST.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Decoy Therapeutics Inc. published the original content used to generate this news brief via PR Newswire  on February 05, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260205:nNDL1HLB7d:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4127","DCOY","BK4139"],"gpt_icon":0},{"id":"2608336724","title":"Decoy Therapeutics gibt Global Access Commitment Agreement mit Gates Foundation bekannt","url":"https://stock-news.laohu8.com/highlight/detail?id=2608336724","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608336724?lang=en_us&edition=fundamental","pubTime":"2026-02-04 22:02","pubTimestamp":1770213738,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Decoy Therapeutics Inc. published the original content used to generate this news brief via PR Newswire  on February 04, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260204:nNDLXHJPq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DCOY","BK4139"],"gpt_icon":0},{"id":"2608417367","title":"Decoy Therapeutics Participates in Virtual Investor \"What This Means\" Segment Highlighting Recently Announced Global Access Commitment Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2608417367","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608417367?lang=en_us&edition=fundamental","pubTime":"2026-02-04 22:02","pubTimestamp":1770213720,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260204:nTUA94F65Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DCOY","BK4139"],"gpt_icon":0},{"id":"2605474750","title":"Decoy Therapeutics initiated with a Buy at Ladenburg","url":"https://stock-news.laohu8.com/highlight/detail?id=2605474750","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605474750?lang=en_us&edition=fundamental","pubTime":"2026-01-23 19:40","pubTimestamp":1769168421,"startTime":"0","endTime":"0","summary":"Ladenburg initiated coverage of Decoy Therapeutics (DCOY) with a Buy rating and $2.50 price target Published first on TheFly – the ultimate source ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/decoy-therapeutics-initiated-with-a-buy-at-ladenburg-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/decoy-therapeutics-initiated-with-a-buy-at-ladenburg-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4139","DCOY","BK4539","BK4007"],"gpt_icon":0},{"id":"2603687051","title":"BUZZ-U.S. STOCKS ON THE MOVE-Cardinal Health, Decoy Therapeutic","url":"https://stock-news.laohu8.com/highlight/detail?id=2603687051","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603687051?lang=en_us&edition=fundamental","pubTime":"2026-01-13 22:06","pubTimestamp":1768313211,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Cardinal Health, Decoy TherapeuticEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter:","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nL6N3YE0U8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4602","LU0477156953.USD","BK4561","LU0203345920.USD","CAH","LU1823568750.SGD","BK4187","IE00BZ1G4Q59.USD","LU2860962120.EUR","LU0642271901.SGD","LU0289960550.SGD","LU0477156797.USD","LU1988902786.USD","LU2108987350.USD","LU1992135472.HKD","LU1496350171.SGD","LU1201861249.SGD","LU2125909759.SGD","LU0496365809.HKD","LU0056508442.USD","BK4525","LU0965509010.AUD","BK4505","IE00BN8TJ469.HKD","LU0211328371.USD","LU0342679015.USD","LU1861214812.USD","LU0882574139.USD","LU0719512351.SGD","LU1046421795.USD","LU0708995401.HKD","BK4017","LU0234572021.USD","LU0889566641.SGD","LU2242649171.HKD","LU0149725797.USD","LU0348723411.USD","LU2089284900.SGD","LU0210533765.USD","LU0251132253.USD","LU1261432733.SGD","LU1363072403.SGD","LU1778281490.HKD","LU0320765489.SGD","IE00B1XK9C88.USD","LU1642822529.SGD","SGXZ51526630.SGD","LU0256331488.USD","LU0210536198.USD","IE00BLSP4239.USD","IE00BJTD4N35.SGD","LU0006061336.USD","LU0868494617.USD","LU1366333091.USD","LU0823421416.USD","BK4603","LU0072461881.USD","LU2237443978.SGD","LU0069063385.USD","LU1623119135.USD","LU1116320737.USD","BK4534","LU0965509101.SGD","LU2247934214.USD","LU0096362180.USD","BK4604","LU0980610538.SGD","LU1894683264.USD","BK4106","LU0353189763.USD","LU1242518931.SGD","LU0265550946.USD","LU0964807845.USD","BK4605","LU2592432038.USD","LU1280957306.USD","LU0640476718.USD","LU2413666699.HKD","LU0957791311.USD","LU0130102774.USD","LU0162691827.USD","BK4535","LU1815333072.USD","LU2237438978.USD","LU2505996509.AUD","BK4551","IE0034235295.USD","IE00B19Z8X17.USD","LU0057025933.USD","BK4207","LU1668664300.SGD","LU1116320901.HKD","BK4500","LU2065171402.SGD","LU1551013425.SGD","LU2362540622.SGD","LU1244550221.USD","BK4587","LU2458330169.SGD","IE00B3CCJ963.GBP","LU1232071149.USD","LU0820561818.USD","LU0345780281.USD","BK4175","LU1267930227.SGD","LU1861558580.USD","IE0004445239.USD","LU0648001328.SGD","LU0130103400.USD","LU2462157665.USD","LU0823434583.USD","BK4579","LU0957808578.USD","IE00BFXG1179.USD","BK4135","LU1032466523.USD","LU1691799644.USD","LU2756315664.SGD","LU0672654240.SGD","LU0300736062.USD","LU2237443622.USD","IE00B3S45H60.SGD","LU1435385759.SGD","BK4516","LU0310799852.SGD","LU0203347892.USD","LU0345769128.USD","LU2098885051.SGD","BK4161","LU2417539215.USD","LU0106261372.USD","SG9999002232.USD","LU2087625088.SGD","LU0122376428.USD","LU0109392836.USD","LU2265009873.SGD","LU2362541513.USD","LU0321505439.SGD","LU1069344957.HKD","LU2023250843.SGD","IE00B775SV38.USD","LU0266512127.USD","LU0861579265.USD","LU2505996681.GBP","BK4575","LU1242518857.USD","IE00BDCRKT87.USD","LU1223083913.SGD","LU1429558221.USD","BK4592","LU2125909593.SGD","BK4213","LU2264538146.SGD","LU2456880835.USD","LU0154236417.USD","LU0689472784.USD","LU1064131342.USD","LU1035775433.USD","LU0130517989.USD","LU0323591593.USD","LU0345780521.USD","LU0300736492.USD","LU0820562030.AUD","LU2543165471.USD","SG9999001424.SGD","LU2210150020.SGD","LU2430703251.USD","IE00BJTD4V19.USD","BK4023","LU0211326755.USD","IE00BKDWB100.SGD","LU1074936037.SGD","SG9999000418.SGD","BK4559","LU0225283273.USD","LU0943347566.SGD","LU2089283258.USD","LU0788109394.HKD","LU0823411888.USD","LU1084165304.USD","LU1720051017.SGD","LU2746668974.SGD","LU0289739343.SGD","SG9999001440.SGD","IE00BQXX3D17.EUR","LU1633808545.USD","LU0965509283.SGD","LU2125154778.USD","IE00BQXX3C00.GBP","LU0203202063.USD","LU2211814178.USD","LU0256863902.USD","LU0274383776.USD","LU2430703095.HKD","LU1430594728.SGD","LU0079474960.USD","SG9999004303.SGD","LU0823434740.USD","LU1803068979.SGD","IE00B5949003.HKD","BK4550","LU1951200564.SGD","LU2237443549.SGD","LU0889565833.HKD","LU0310800965.SGD","IE00BYXW3230.USD","LU1145028129.USD","BK4220","LU2065171311.SGD","IE00B2Q91V27.USD","BK4613","LU2756315318.SGD","LU0942090050.USD","LU0052756011.USD","IE0034235303.USD","LU1861219969.SGD","LU0648000940.SGD","BK4141","LU2250418816.HKD","LU0345780950.USD","BK4543","LU1861215975.USD","LU1923623000.USD","BK4529","LU2433249047.HKD","LU2023250330.USD","LU0208291251.USD","LU1267930730.SGD","LU0130518102.USD","LU1854104046.USD","LU2065170008.USD","LU0823421333.USD","LU0820561909.HKD","LU0198837287.USD","LU1699723380.USD","LU1223082196.USD","IE00BQXX3F31.USD","LU2317271919.USD","LU0979878070.USD","IE00BHPRN162.USD","LU2211815571.USD","LU2125154935.USD","LU0158827948.USD","LU2125909247.SGD","BK4612","LU2362541273.HKD","BK4567","LU1821325948.USD","BK4570","LU0557290698.USD","LU2089985449.USD","LU0314106906.USD","LU0320765646.SGD","LU0321505868.SGD","LU0472753341.HKD","SGXZ99366536.SGD","LU2148611432.USD","LU0345774391.USD","BK4573","LU0265550359.USD","LU1712237335.SGD","LU1670628061.USD","LU1989764748.USD","LU0456854461.SGD","IE00BYQQ9H92.USD","LU1894683348.USD","LU0082616367.USD","BK4560","LU0976567544.SGD","LU1923622291.USD","LU2023250504.SGD","LU0630314457.HKD","LU2931357623.SGD","LU1267930490.SGD","LU1316542783.SGD","LU1674673428.USD","IE00BBT3K403.USD","LU1951198990.SGD","LU1244550494.USD","LU2237443895.HKD","LU1119994496.HKD","BK4226","LU0238689110.USD","LU2357305700.SGD","IE000M9KFDE8.USD","LU0127658192.USD","IE0009356076.USD","BK4527","LU2065169927.USD","SG9999002224.SGD","BK4007","LU0203201768.USD","LU1267930813.SGD","LU0320765059.SGD","LU2361044865.SGD","LU0289961442.SGD","LU0787776722.HKD","LU1804176565.USD","DCOY","LU2237443465.HKD","LU1585245621.USD","LU1496350502.SGD","LU0347712357.USD","LU1303367103.USD","LU1914381329.SGD","LU2746668461.USD","LU2552382132.HKD","BK4524","LU2063271972.USD","LU1989764664.SGD","BK4554","LU1861559042.SGD","BK4089","LU0368265418.SGD","LU2355687059.USD","LU0345781412.USD","LU2326559502.SGD","LU0444971666.USD","IE0034235188.USD","LU1852331112.SGD","LU0006306889.USD","IE00B1BXHZ80.USD","LU0971096721.USD","BK4512","BK4210","BK4504","LU1992135399.USD","BK4155","LU0211327993.USD","BK4108","LU2413666426.HKD","BK4114","BK4548","LU2360107168.USD","LU0175139822.USD","BK4566","IE00BKPKM429.USD","LU1814569148.SGD","IE00BZ9MQY76.HKD","IE00BFXG0V08.USD","LU1721428933.USD","SGXZ23171101.USD","LU0417517546.SGD","LU0215105999.USD","LU2361045086.USD","LU1861220033.SGD","LU1923622614.USD","LU0256863811.USD","LU0211326839.USD","LU2381873111.SGD","LU0267386448.USD","LU2106854487.HKD","LU0061474960.USD","LU2213496289.HKD","LU0792757196.USD","LU1201861165.SGD","BK4515","BK4150","IE00BZ199S13.USD","LU2286300806.USD","LU0077335932.USD","LU2272731600.USD","BK4097","LU0157215616.USD","LU2360106780.USD","IE00B894F039.SGD","LU2552382215.SGD","LU1917777945.USD","LU1854103824.USD","LU2458330243.SGD","LU1366192091.USD","LU2125909916.SGD","LU0187121727.USD","BK4581","IE00BGHQF524.EUR","LU0128525689.USD","LU1880398471.USD","LU1223082519.USD","LU0109391861.USD","LU2290526834.HKD","IE00B19Z8W00.USD","BK4122","LU2237957902.USD","BK4614","IE00B5TLWC47.USD","LU0070302665.USD","LU1720051108.HKD","LU2023251221.USD","LU1506573853.SGD","IE00BFMHRM44.USD","LU1815336760.USD","LU2210149790.SGD","LU0868494708.USD","LU2272731782.SGD","LU2244417387.USD","LU2360032135.SGD","SGXZ81514606.USD","BK4588","BK4597","LU0081259029.USD","LU0353189680.USD","BK4564","IE00BWXC8680.SGD","LU2896262040.SGD","LU1551013342.USD","LU1235294995.USD","IE00B19Z9P08.USD","LU1127390331.HKD","LU0234570918.USD","LU0683600562.USD","IE00BMPRXR70.SGD","LU1670627923.USD","LU1674673691.USD","LU2430703178.SGD","CPNG","LU0345774631.USD","IE00B19Z9Z06.USD","LU1571399168.USD","BK4532","LU2461242641.AUD","LU0170899867.USD","LU1629891620.HKD","LU0048584097.USD","LU1244550577.SGD","LU2237957811.SGD","LU2361044949.HKD","LU0211331839.USD","LU0345770308.USD","LU0511384066.AUD","IE00BKVL7J92.USD","LU1974910355.USD","IE00B19Z9505.USD","LU2237443382.USD","LU0106831901.USD","IE0009354923.USD","LU1929549753.HKD","IE00BDRTCR15.USD","LU2360107325.USD","LU0314104364.USD","LU2095319765.USD","BK4507","LU0390134368.USD","LU2552382058.USD","BK4528","LU1162221912.USD","LU1880398554.USD","IE00BLSP4452.SGD","IE0008368304.USD","LU2054465674.USD","LU0097036916.USD","BK4139","BK4598","LU2236285917.USD","LU0345769631.USD","LU0786609619.USD","LU0345770993.USD","BK4585","BK4147","BK4008","BK4100","LU1548497426.USD","BK4596","BK4519","IE00BMPRXN33.USD","BK4533","IE00BJLML261.HKD"],"gpt_icon":0},{"id":"2603024684","title":"BUZZ-Decoy Therapeutics rises as Gates Foundation backs antiviral drug access","url":"https://stock-news.laohu8.com/highlight/detail?id=2603024684","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603024684?lang=en_us&edition=fundamental","pubTime":"2026-01-13 21:24","pubTimestamp":1768310693,"startTime":"0","endTime":"0","summary":"BUZZ-Decoy Therapeutics rises as Gates Foundation backs antiviral drug access** Shares of drug developer Decoy Therapeutics DCOY.O rise 6.99% to $0.872 premarket ** Co says it has reached agreement with Gates Foundation to develop manufacturing platform for antiviral drugs** Platform aims to make antivirals widely available in low- and middle-income countries, co says** Technology called IMP3ACT enables rapid design and production of drugs for viruses such as flu and people with weakened immune systems, co adds** Co plans to validate platform with experimental nasal spray to prevent coronavirus infections in immunocompromised people** Lead antiviral candidate expected to be submitted to U.S. regulators within a year, DCOY says** As of last close, stock down ~97% over past year  ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nL4N3YE17R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DCOY"],"gpt_icon":0},{"id":"2603841196","title":"Decoy Therapeutics Advances Pan-Coronavirus Antiviral Toward FDA IND Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2603841196","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603841196?lang=en_us&edition=fundamental","pubTime":"2026-01-13 21:15","pubTimestamp":1768310128,"startTime":"0","endTime":"0","summary":"Decoy Therapeutics Inc. announced plans to advance its pipeline of peptide conjugate therapeutics using its proprietary IMP3ACT platform, with a focus on making countermeasures for emerging pathogens accessible to low- and middle-income countries. The company expects to file an Investigational New Drug  application with the U.S. FDA for its lead asset, a pan-coronavirus antiviral, within the next 12 months. Additionally, Decoy is progressing on other programs, including a broad-acting antiviral for flu, COVID-19, and RSV, as well as a peptide drug conjugate targeting GI cancers. The company’s intranasal pan-coronavirus fusion inhibitor, which demonstrates the IMP3ACT platform’s design-for-manufacturing capability, will be used to validate Decoy’s new distributed manufacturing network. The results of these research and development efforts will be presented in the future.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT s","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nNDLbYn7Lp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DCOY","BK4139"],"gpt_icon":0},{"id":"2603968490","title":"Decoy Therapeutics Reaches Global Access Commitment Agreement to Focus on Development of a Globally Accessible, Scalable Peptide-Conjugate Manufacturing Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2603968490","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603968490?lang=en_us&edition=fundamental","pubTime":"2026-01-13 21:15","pubTimestamp":1768310105,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nTUAKK3M2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","DCOY"],"gpt_icon":0},{"id":"2603844586","title":"Decoy Therapeutics Inc - Expects to File Ind Application for Pan-Coronavirus Antiviral","url":"https://stock-news.laohu8.com/highlight/detail?id=2603844586","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603844586?lang=en_us&edition=fundamental","pubTime":"2026-01-13 21:15","pubTimestamp":1768310105,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nTUAKK3M2:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","DCOY"],"gpt_icon":0},{"id":"2601092538","title":"BRIEF-Salarius Pharmaceuticals Changes Name To Decoy Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2601092538","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601092538?lang=en_us&edition=fundamental","pubTime":"2026-01-07 22:22","pubTimestamp":1767795755,"startTime":"0","endTime":"0","summary":"BRIEF-Salarius Pharmaceuticals Changes Name To Decoy TherapeuticsJan 7 (Reuters) - Salarius Pharmaceuticals Inc SLRX.O:SALARIUS PHARMACEUTICALS INC - CHANGES NAME TO DECOY THERAPEUTICSSALARIUS PHARMAC","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nFWN3Y80D6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLRX","DCOY"],"gpt_icon":0},{"id":"2601806365","title":"Salarius Pharmaceuticals Inc - Changes Name to Decoy Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2601806365","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601806365?lang=en_us&edition=fundamental","pubTime":"2026-01-07 21:45","pubTimestamp":1767793519,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nFWN3Y80D6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","DCOY","SLRX"],"gpt_icon":0},{"id":"2601366806","title":"Salarius Pharmaceuticals Inc - Trading Under Dcoy to Commence on January 8, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2601366806","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601366806?lang=en_us&edition=fundamental","pubTime":"2026-01-07 21:45","pubTimestamp":1767793519,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nFWN3Y80D6:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DCOY","BK4139","SLRX"],"gpt_icon":0},{"id":"2601360806","title":"Salarius Pharmaceuticals Rebrands as Decoy Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2601360806","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601360806?lang=en_us&edition=fundamental","pubTime":"2026-01-07 21:45","pubTimestamp":1767793510,"startTime":"0","endTime":"0","summary":"Salarius Pharmaceuticals Inc. has announced it will change its corporate name to Decoy Therapeutics Inc. and will trade on the Nasdaq Capital Market under the ticker symbol DCOY, reflecting the company's focus on developing next-generation peptide-conjugate therapeutics.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Salarius Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire  on January 07, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nNDL1M80Gp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","SLRX","IE00BGHQF748.EUR","NDAQ","LU2210149790.SGD","BK4588","SG9999014005.SGD","BK4112","IE00B64PRP62.GBP","LU2095319765.USD","IE00B3QW5Z07.USD","SG9999014039.USD","BK4585","SG9999014021.USD","IE00BKPKM429.USD","DCOY","LU2210150020.SGD","BK4139","SG9999014013.SGD"],"gpt_icon":0},{"id":"2601831965","title":"Top Midday Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2601831965","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601831965?lang=en_us&edition=fundamental","pubTime":"2026-01-06 03:00","pubTimestamp":1767639627,"startTime":"0","endTime":"0","summary":"Zenas BioPharma (ZBIO) reported Monday that a phase 3 trial of obexelimab in immunoglobulin G4-related disease showed a 56% reduction in the risk of disease flare.However, Amgen (AMGN) had won approva","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SG9999014880.SGD","IE0002141913.USD","LU2089984988.USD","AMGN","SLRX","SGXZ31699556.SGD","LU0868494617.USD","LU1861215975.USD","LU2242646821.SGD","SG9999001440.SGD","LU2112291526.USD","LU0889565916.HKD","LU1571399168.USD","BK4145","DCOY","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","BK4139","SG9999014906.USD","SG9999018857.SGD","LU1023059063.AUD","SG9999018865.SGD","IE00BJJMRZ35.SGD","LU2468319806.SGD","LU0109394709.USD","LU1057294990.SGD","SG9999014914.USD","LU0122379950.USD","SG9999014898.SGD","JBL","LU0058720904.USD","LU1861220033.SGD","SG9999017495.SGD","IE0009355771.USD","BK4599","LU0320765992.SGD","BK4585","BK4534","LU2242652126.USD","BK4581","ZBIO","BK4588","LU1983299246.USD","BK4566","LU1814569148.SGD","IE00B2B36J28.USD","IE00BJT1NW94.SGD","LU1169590202.USD","BK4512","BK4533"],"gpt_icon":0},{"id":"2600953170","title":"Nasdaq Moves to Delist Salarius Pharmaceuticals Over Minimum Bid Price Violation","url":"https://stock-news.laohu8.com/highlight/detail?id=2600953170","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600953170?lang=en_us&edition=fundamental","pubTime":"2026-01-03 06:15","pubTimestamp":1767392115,"startTime":"0","endTime":"0","summary":"Salarius Pharmaceuticals Inc. is facing potential delisting from the Nasdaq Capital Market after receiving notice that its common stock has failed to meet the minimum bid price requirement of $1.00 for 30 consecutive business days. Due to a recent reverse stock split, the company is not eligible for the usual 180-day compliance period and must appeal the decision to a Nasdaq Hearings Panel by January 7, 2026, to avoid suspension of its securities. There is no assurance that Salarius will successfully regain compliance or maintain its Nasdaq listing.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Salarius Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analys","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260102:nNDL9Hry86:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DCOY","SLRX"],"gpt_icon":0},{"id":"2600095348","title":"Director Arnold C. Hanish Reports Disposal of Salarius Pharmaceuticals Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2600095348","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600095348?lang=en_us&edition=fundamental","pubTime":"2026-01-03 06:14","pubTimestamp":1767392066,"startTime":"0","endTime":"0","summary":"Arnold C. Hanish, Director at Salarius Pharmaceuticals Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Salarius Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 02, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260102:nNDL8Cltv8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Director Arnold C. Hanish Reports Disposal of Salarius Pharmaceuticals Inc. Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DCOY","SLRX"],"gpt_icon":0},{"id":"2600095825","title":"Salarius Pharmaceuticals Inc. held annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2600095825","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600095825?lang=en_us&edition=fundamental","pubTime":"2026-01-03 06:13","pubTimestamp":1767392033,"startTime":"0","endTime":"0","summary":"Salarius Pharmaceuticals Inc. held its annual meeting of stockholders on December 31, 2025. During the meeting, stockholders re-elected two Class I directors to the board. Stockholders also approved the appointment of Ernst & Young LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2025. All proposals presented at the meeting were approved.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Salarius Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 02, 2026, and is solely responsible for the information contain","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260102:nNDLdzTjV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DCOY","SLRX","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":17,"code":"91000000","status":"200"}]}}